Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
11 hedge funds and large institutions have $7.5M invested in Soleno Therapeutics in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
57% more funds holding
Funds holding: 7 → 11 (+4)
24% less capital invested
Capital invested by funds: $9.87M → $7.5M (-$2.37M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$26.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$24K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.29K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$1.14K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$228 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$258K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VC
1
Vivo Capital
Palo Alto,
California
| $6.71M | – | – | – |
|
|
BG
2
Bollard Group
Boston,
Massachusetts
| $363K | – | – | – |
|
|
SM
3
Sabby Management
Miami Beach,
Florida
| $236K | -$258K | -3,407 | -51% |
|
|
BIT
4
BlackRock Institutional Trust
San Francisco,
California
| $68K | – | – | – |
|
5
Vanguard Group
Malvern,
Pennsylvania
| $59K | – | – | – |
|
|
6
Goldman Sachs
New York
| $24K | +$26.6K | +351 | New |
|
|
7
Citadel Advisors
Miami,
Florida
| $23K | +$24K | +317 | New |
|
|
VKH
8
Virtu KCG Holdings
New York
| $10K | +$1.14K | +15 | +11% |
|
|
BFA
9
BlackRock Fund Advisors
San Francisco,
California
| $1K | +$152 | +2 | +17% |
|
|
10
Bank of America
Charlotte,
North Carolina
| $1K | +$1.29K | +17 | New |
|
|
11
UBS Group
Zurich,
Switzerland
| – | +$228 | +3 | New |
|
SLNO Hedge Fund Activity: Q3 2016 in Review
11 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q3 2016, worth a combined $7.5M — down 24% from $9.87M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SLNO positions and 0 closed out — a net gain of 4 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $26.6K. The largest seller was Sabby Management, cutting an estimated $258K.
- 11 institutional investors held Soleno Therapeutics (SLNO) as of Q3 2016, up from 7 in Q2 2016.
- Funds reported $7.5M of Soleno Therapeutics stock for Q3 2016, down 24% quarter-over-quarter.
- 4 funds opened new Soleno Therapeutics positions in Q3 2016 and 0 closed out, a net change of +4 holders.
- The largest Soleno Therapeutics buyer in Q3 2016 was Goldman Sachs, an estimated $26.6K added.
- The largest Soleno Therapeutics seller in Q3 2016 was Sabby Management, an estimated $258K sold.
Based on aggregated 13F filings for Q3 2016.